On Eve of Earnings, Compugen Extends Deal with Novartis to Cover Systems Bio | GenomeWeb

Last Tuesday, the day before it reported its first-quarter financial results, Compugen announced that it had extended its existing relationship with Novartis into the realm of systems biology.

The timing of the disclosure was no coincidence. Martin Gerstel, Compugen's chairman, opened an analyst conference call on Wednesday with an explanation of how the company has been practicing systems biology "for almost a decade," even if the term is only now catching on in the broader life science community.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.